Ipsen Manufacturing
Ipsen is a biotechnological group aiming to become a leader in specialty healthcare solutions for debilitating diseases. Its strategy is supported by three franchises, neurology, endocrinology and urology-oncology.
Ipsen has a growing portfolio in prostate cancer, bladder cancer or neuro-endocrine tumours and a presence in primary care.
The group has more than 4,500 employees spread across R&D and manufacturing sites located in China, France, Ireland, the UK and the US.
Financial Data
-
31st Dec 17 Source: CRO
- €122.2 million turnover
-
€104 million
profit - 125 employees
-
31st Dec 16 Source: CRO
- €103 million turnover
-
€85.7 million
profit - 111 employees
- 5 more years available »
Ranking
By Turnover
(€122.2 million)- 425th in Top Companies
- 48th in Health
- 43rd in Pharma
- 65th in Manufacturing
By Employees
(125)- 663rd in Top Companies
- 81st in Health
- 62nd in Pharma
- 100th in Manufacturing
- 125
- €122.2 million
Employees
- James Byrne General Manager
Latest News
- 7:54pm Amarin to seek European approval for heart drug Vascepa
- 7:31pm Markets spooked by US-China trade row
- 5:44pm US to signal approval of $26.5bn T-Mobile US and Sprint merger
- 5:42pm Intel gets green light for $4bn development at Leixlip
- 5:15pm Hong Kong ‘worried’ over short-term impact of US-China trade war